



Patient Information	
Name:	_____
DOB:	_____
Address:	_____
City:	State: _____
Zip:	Weight: _____
Phone:	_____
Allergies:	_____

Prescriber Information	
Prescriber Name:	_____
NPI:	_____
Address:	_____
City:	_____
State:	Zip: _____
Phone:	_____

Diagnosis (please provide ICD-10 code in space provided):	
_____ Myasthenia Gravis without (acute) exacerbation	_____ Myasthenia Gravis with (acute) exacerbation
_____ Other: _____	

Nursing Orders: Hold infusion and notify provider for:

Signs/symptoms of illness or active infection, planned/recent surgical procedures, cough, night sweats, unintended weight loss, recent live vaccinations, active shingles. If infusion related reaction occurs, stop infusion and follow Hypersensitivity Reaction Management Policy/Protocol as clinically indicated.

Premedications:
<input type="checkbox"/> Tylenol 650mg PO <input type="checkbox"/> Benadryl 25mg IV or PO <input type="checkbox"/> Solu-Medrol IV 40mg, 125mg or _____ mg <input type="checkbox"/> Other: _____ IV or PO
Order valid for one year unless otherwise indicated. IV solutions and diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability

<input type="checkbox"/> Vyvgart IV	<input type="checkbox"/> Infuse IV 10 mg/kg (Dose = _____ mg) weekly for 4 weeks (1 cycle). Infuse over 1 hour. Mixed in 100 ml 0.9% sodium chloride. <input type="checkbox"/> Infuse _____ mg/kg (Dose = _____ mg) weekly for _____ weeks. (1 cycle). Infuse over _____ hour(s). Mixed in 100 ml 0.9% sodium chloride. Subsequent treatment cycles must be based on clinical evaluation and no sooner than 50 days from the start of the previous treatment cycle. Use in-line, sterile, non-pyrogenic filter (pore size 0.2 micron).
<input type="checkbox"/> Vyvgart Hytrulo SQ	<input type="checkbox"/> 5.6 ml (efgartigimod alfa 1,008 mg and hyaluronidase 11,200 units) administered weekly for 4 weeks Inject via SubQ push over 30-90 seconds <input type="checkbox"/> Other: _____ Subsequent treatment cycles must be based on clinical evaluation and no sooner than 50 days from the start of the previous treatment cycle.

Prescriber Name (Please print): _____
 Prescriber Signature: _____ Date: _____

Please include a copy of the latest insurance information as well as all applicable clinical notes.

Email to: orders@alliedinfusion.com Fax to: 832-698-3961